在晚期泌尿腺癌中治疗顺序
Irbaz B Riaz1, Muhammad Abdullah Humayun1, Ali Raza Khaki2
1Mayo Clinic, Phoenix, AZ, USA.
Drugs
|January 18, 2026
概括
新的尿路癌治疗方法,如恩福图马布 (enfortumab) 维多丁 (vedotin) 加上潘布罗利祖马布 ( pembrolizumab),提供了生存益处,但面临着进入障碍. 替代疗法和测序策略对于更广泛的患者获取和有效的护理至关重要.
科学领域:
- 在瘤学瘤学.
- 尿癌治疗方法 尿癌治疗方法
- 癌症治疗方法 癌症治疗方法
背景情况:
- 先进的泌尿腺癌治疗已经通过抗体-药物合物和免疫疗法发展.
- 恩福图马布 (vedotin) 加上潘布罗利祖马布 ( pembrolizumab) 显示了比化疗更好的生存率,但存在成本和可用性问题.
- 已确立的替代方案包括结合尼沃卢马布和基于的化学疗法与维护阿维卢马布的格姆西塔-西斯普拉丁.
研究的目的:
- 审查目前关于先进泌尿腺癌治疗范式的证据.
- 为了应对因恩福图马布维多丁加布罗利祖马布失败后治疗顺序的挑战.
- 突出全球实施的实际考虑,平衡创新与获取和成本效益.
主要方法:
- 最近临床试验的文献综述和关于晚期泌尿腺癌的证据.
- 对新型药物和测序策略的数据的综合.
- 对治疗选择的成本,可用性和全球适用性的分析.
主要成果:
- 恩福图马布维多丁加上布罗利祖马布可以显著提高生存率,但受到成本和获取的限制.
- 替代疗法仍然至关重要,特别是对于能够接受西斯的患者或在资源有限的环境中.
- 进展后的选择包括恩福图马布维多丁单疗法,厄尔达菲提尼布用于FGFR3变异,以及特拉斯图祖马布德鲁克斯坦用于HER2阳性疾病.
结论:
- 在恩福图马布 (vedotin) 和布罗利祖马布 ( pembrolizumab) 后的治疗顺序需要进一步研究.
- 循环瘤DNA显示了个性化测序的前景,但仍在研究中.
- 未来的优先事项包括平衡创新与公平获取,成本效益和在尿癌治疗中的全球适用性.
相关概念视频
03:55Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
941
In diagnosing and treating locally advanced thyroid cancer, the application of computer-aided three-dimensional reconstruction can provide additional information regarding the tumor scope and anatomic characteristics, thereby assisting in risk assessment and surgical...
941
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
2.7K
This protocol describes the orthotopic implantation of patient-derived cancer cells in the cecum wall of immunodeficient mice. The model recapitulates advanced colorectal cancer metastatic disease and allows for the evaluation of new therapeutic drugs in a clinically relevant scenario of lung and liver...
2.7K
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
353
This protocol describes an automated, ISO15189-accredited next-generation sequencing workflow for detecting targetable genomic alterations in non-small cell lung cancer (NSCLC) formalin-fixed paraffin-embedded...
353
09:16Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
3.0K
This protocol describes the process of the generation and characterization of mouse urothelial organoids harboring deletions in genes of interest. The methods include harvesting mouse urothelial cells, ex vivo transduction with adenovirus driving Cre expression with a CMV promoter, and in vitro as well as in vivo...
3.0K
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
20.1K
Pancreatic cancer stem cells (CSCs) can be expanded in vitro using the anchorage-independent sphere culture technique, which represents a powerful tool to study CSC biology and can serve as the first step to develop novel CSC-targeting therapies. Here the methodology for expanding, analyzing and targeting of pancreatic CSCs is...
20.1K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K